The potential of gene therapy could turn what if’s into what’s next for people living with serious diseases. Designed for healthcare professionals who treat patients with genetic conditions, this website provides educational information to help you better understand this rapidly advancing field.

Gain a foundation in gene therapy

Learn about the fundamentals of cell and genetic therapy, the different gene-therapy tools, and the range of delivery methods.

Discover gene therapy
DNA strand icon representing gene therapy  methods
DNA strand icon representing gene therapy  methods

Discover the field of gene editing

Review the latest technologies for gene editing—a type of gene therapy that aims to precisely target and modify a patient’s genes.10

Explore gene editing
ACGT letters graphic representing DNA code
ACGT letters graphic representing DNA code

Learn how gene addition works

Read about a type of gene therapy that seeks to add a functional copy of a faulty gene into the genome to affect protein expression.11-13

Understand gene addition
Two DNA strand icons joined by plus sign  representing gene addition
Two DNA strand icons joined by plus sign  representing gene addition

Get up to speed with more expert knowledge

This website is just one part of your learning journey. Dig deeper with links to published articles and other gene-therapy resources.

Visit library
Lab microscope icon representing gene therapy library
Lab microscope icon representing gene therapy library

Our commitment to you

Vertex Pharmaceuticals is committed to providing healthcare professionals with educational information about gene therapy.

Vertex Pharmaceuticals logo
Vertex Pharmaceuticals logo

Sign up to stay informed

Stay with Vertex as we continue to explore the evolving field of gene therapy.

Sign up

References: 1. Jain S, Shukla S, Yang C, et al. TALEN outperforms Cas9 in editing heterochromatin target sites. Nat Commun. 2021;12(1):606. doi:10.1038/s41467-020-20672-5. 2. Maeder ML, Gersbach CA. Genome-editing technologies for gene and cell therapy. Mol Ther. 2016;24(3):430-446. doi:10.1038/mt.2016.10. 3. Simeon M, Dangwal S, Sachinidis A, Doss MX. Application of the pluripotent stem cells and genomics in cardiovascular research—what we have learnt and not learnt until now. Cells. 2021;10(11):3112. doi:10.3390/cells10113112. 4. Fathallah MD. Genomics, gene editing and biologics: the bolsters of the new medical paradigm. Curr Trends Biomedical Eng Biosci. 2017;6(4):1-4. doi:10.19080/CTBEB.2017.06.555694. 5. Sudhakar V, Richardson RM. Gene therapy for neurodegenerative diseases. Neurotherapeutics. 2019;16(1):166-175. doi:10.1007/s13311-018-00694-0. 6. Amado DA, Davidson BL. Gene therapy for ALS: a review. Mol Ther. 2021;29(12):3345-3358. doi:10.1016/j.ymthe.2021.04.008. 7. Dias MF, Joo K, Kemp JA, et al. Molecular genetics and emerging therapies for retinitis pigmentosa: basic research and clinical perspectives. Prog Retin Eye Res. 2018;63:107-131. doi:10.1016/j.preteyeres.2017.10.004. 8. Gene therapy. ClinicalTrials.gov. Accessed April 14, 2023. https://clinicaltrials.gov/ct2/results?cond=&term=gene+therapy&cntry=US&state=&city=&dist. 9. Approved cellular and gene therapy products. US Food & Drug Administration. Updated October 26, 2021. Accessed April 14, 2023. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products. 10. Li H, Yang Y, Hong W, Huang M, Wu M, Zhao X. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther. 2020;5(1):1. doi:10.1038/s41392-019-0089-y. 11. DeWeerdt S. Gene therapy: a treatment coming of age. Pharm J. 2014;293(7831). doi:10.1211/PJ.2014.20066677. 12. Dong AC, Rivella S. Gene addition strategies for ß-thalassemia and sickle cell anemia. Adv Exp Med Biol. 2017;1013:155-176. doi:10.1007/978-1-4939-7299-9_6. 13. Nowakowski A, Andrzejewska A, Janowski M, Walczak P, Lukomska B. Genetic engineering of stem cells for enhanced therapy. Acta Neurobiol Exp. 2013;73:1-18.